Reply

Affiliations

Comment

Arpan Jain et al. Hepatology. 2022 Apr.

. 2022 Apr;75(4):1066-1067.

doi: 10.1002/hep.32305. Epub 2022 Jan 12.

No abstract available

Comment on

Letter to the editor: Episodic-precipitant-induced hepatic encephalopathy treatment: Look at new and old precipitants!
Ridola L, Nardelli S, Gioia S, Faccioli J, Riggio O. Ridola L, et al. Hepatology. 2022 Apr;75(4):1065-1066. doi: 10.1002/hep.32306. Epub 2022 Feb 10. Hepatology. 2022. PMID: 34951720 No abstract available.
Letter to the editor: Evidence on the use of l-ornithine l-aspartate in overt HE-But does it really improve prognosis?
Labenz C, Labenz J, Galle PR. Labenz C, et al. Hepatology. 2022 Apr;75(4):1064-1065. doi: 10.1002/hep.32309. Epub 2022 Jan 12. Hepatology. 2022. PMID: 34957567 No abstract available.

1. Jain A, Sharma BC, Mahajan B, Srivastava S, Kumar A, Sachdeva S, et al. l ‐Ornithine l ‐aspartate in acute treatment of severe hepatic encephalopathy: a double‐blind randomized controlled trial. Hepatology. 2021. https://doi.org/10.1002/hep.32255 - DOI
1. Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC, et al. Acute‐on‐chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int. 2014;8(4):453–71.
1. Ahmad I, Khan AA, Alam A, Dilshad A, Butt AK, Shafqat F, et al. l ‐Ornithine‐ l ‐aspartate infusion efficacy in hepatic encephalopathy. J Coll Physicians Surg‐Pak. 2008;18(11):684–7.
1. Sidhu SS, Sharma BC, Goyal O, Kishore H, Kaur N. l ‐Ornithine l ‐aspartate in bouts of overt hepatic encephalopathy. Hepatology. 2018;67(2):700–10.
1. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK, et al. A randomized, double‐blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108(9):1458–63.